

PREPARATION OF MANUSCRIPTS

Authors are strongly recommended to read the full *Instructions to Authors and Nomenclature Guidelines for Authors* (*Br. J. Pharmacol.* 1996, **117**, 389–399) before submitting a manuscript for publication in the *British Journal of Pharmacology*. The manuscript and cover letter should be checked against the following list before mailing.

The original and one copy of the manuscript must be supplied. Manuscripts must be typed in double-line spacing on one side of A4 paper, in type not smaller than 12 characters per inch or 10 point. Both copies to include Tables and a set of labelled Figures. One set of Figures without numbers or letters is also to be included. The text to be arranged in the following subsections:

1. **Title**—To have no more than 150 characters on a separate page, which should also include a Short Title (50 characters maximum) and the name and address of the author for correspondence.
2. **Summary**—To be arranged in numbered paragraphs (Full Papers) or a single paragraph (Special Reports).
—to include aims, principal results and conclusions.
—to include Key words (10 maximum) at end of summary.
3. **Introduction**—To contain concise statements of the problem and the aims of the investigation.
4. **Methods**—To have brief but adequate account of the procedures; *full names of drugs (including those referred to by manufacturer's code)*, sources of drugs and statistical tests to be stated.
5. **Results**—To have no repetition of data in Figures, Tables and text.
6. **Discussion**—Findings and conclusions to be placed in context of other relevant work.
NB Simple repetition of results and unwarranted speculation are not acceptable.
7. **Acknowledgements**—Sources of support. Sources of drugs not widely available commercially.
8. **References**—All references in the text to be included in the Reference List and *vice versa*. References in alphabetical order with complete citations; Journals publishing 'in press' papers identified.

References to manuscripts submitted to other journals but not yet accepted are not allowed.

9. **Tables**—Each on a separate page and prepared in accordance with current requirements of the Journal.
10. **Figures**—Both labelled and non-labelled Figures to be prepared in accordance with current requirements of the Journal (see *Instructions to Authors*, 1996, **117**, 389–396) and provided with Figure Number and Authors' names on back (*in pencil*).
—each legend to be typed on a separate page and carrying keys to symbols.
—keys to symbols and histograms must not appear on the figures themselves, but in the respective legends.
—'box style' figures are not in keeping with the Journal style; line drawings etc must have only left-hand and bottom axes.
11. **Manuscripts**—To be accompanied by a declaration signed by each author that
 - (a) results are original
 - (b) approval of all persons concerned has been given to submit manuscripts for consideration (see also 12b)
 - (c) the same material is neither 'in press' (i.e. is in proof or has definitely been accepted for publication) nor under consideration elsewhere. Furthermore it will not be submitted or published elsewhere before a decision has been reached by the Editorial Board of the *British Journal of Pharmacology* and will not be submitted elsewhere if accepted by the *British Journal of Pharmacology*.
 - (d) Copyright assignment is included.
12. **Cover letter**—To state clearly
 - (a) Corresponding author's full postal address, telephone, telex or Fax number
 - (b) where appropriate, that *either* ethical approval has been given for investigation *or* Company or Institutional permission to publish work has been received.
13. **Reminder**—Packaging to be sufficiently robust to protect Figures and to withstand mailing.

Failure to comply with *Instructions to Authors* may lead to substantial delays in processing, review and publication and may even jeopardize acceptance of the manuscript.

NOMENCLATURE

Authors are reminded that accepted receptor and associated terminology is laid out in *Nomenclature Guidelines for Authors*, as published in the *British Journal of Pharmacology*, *Br. J. Pharmacol.*, 1996, **117**, 397–399.

SPECIAL REPORTS

The purpose of *Special Reports* is to provide rapid publication for **new** and **important** results which the Editorial Board considers are likely to be of special pharmacological significance. *Special Reports* will have publication priority over all other material and so authors are asked to consider carefully the status of their work before submission.

In order to speed publication there is normally no revision allowed beyond very minor typographical or grammatical corrections. If significant revision is required, the Board may either invite rapid re-submission or, more probably, propose that it be re-written as a Full Paper and be re-submitted for consideration. In order to reduce delays, proofs of *Special Reports* will be sent to authors but **essential corrections must reach the Production Office within 48 hours of receipt**. Authors should ensure that their submitted material conforms exactly to the following requirements. **In a covering letter, the authors should state clearly and briefly, why THEY consider the Report to be of special pharmacological significance and should therefore receive priority for publication as a Special Report.**

Special Reports should normally occupy no more than two printed pages of the Journal; two illustrations (Figures or Tables, with legends) are permitted. As a guideline, with type face of 12 pitch and double-line spacing, a page of A4 paper could contain about 400 words. The absolute maximum length of the *Special Report* is 1700 words. For each Figure or Table, please deduct 200 words. The manuscript should comprise a Title page with key words (maximum of 10), a Summary consisting of a single short paragraph, followed by Introduction, Methods, Results, Discussion and References (maximum of 10). In all other respects, the requirements are the same as for Full Papers (see current 'Instructions to Authors').

BRITISH JOURNAL OF PHARMACOLOGY

The *British Journal of Pharmacology* welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

Edited for the British Pharmacological Society by

A.T. Birmingham
(Chairman)

R.W. Horton **W.A. Large**
(Secretaries)

Editorial Board

P.I. Aaronson *London*
C.J. Bailey *Birmingham*
L. Belardinelli *Gainesville, USA*
Maria G. Belvisi *London*
G.W. Bennett *Nottingham*
T.P. Blackburn *Harlow*
M.R. Boarder *Leicester*
N.G. Bowery *Birmingham*
W.C. Bowman *Glasgow*
R. Busse *Frankfurt, Germany*
S.P. Butcher *Edinburgh*
K.D. Butler *Horsham*
M. Caulfield *Dundee*
R.A.J. Challiss *Leicester*
R. Chess-Williams *Sheffield*
T. Cocks *Melbourne, Australia*
Helen M. Cox *London*
V. Crunelli *Cardiff*
A. Dickenson *London*
J.R. Docherty *Dublin*
L. Edvinsson *Lund, Sweden*
G. Edwards *Manchester*
R.M. Eglen *Palo Alto, USA*
P.C. Emson *Cambridge*
R.H. Evans *Bristol*
A.W. Ford-Hutchinson *Quebec, Canada*
A.C. Foster *San Diego, USA*
J.R. Fozard *Basle, Switzerland*
B.B. Fredholm *Stockholm, Sweden*
Allison D. Fryer *Baltimore, USA*
J.P. Gallagher *Galveston, USA*

Sheila M. Gardiner *Nottingham*
C.J. Garland *Bristol*
A. Gibson *London*
M.A. Gienbycz *London*
W.R. Giles *Calgary, Canada*
R.G. Goldie *Perth, Australia*
R.J. Griffiths *Groton, USA*
R.W. Gristwood *Cambridge*
Judith M. Hall *Guildford*
D.W.P. Hay *Philadelphia, USA*
D.J. Heal *Nottingham*
P.G. Hellewell *London*
K. Hillier *Southampton*
P. Holzer *Graz, Austria*
S.M.O. Hourani *Guildford*
D. Hoyer *Basle, Switzerland*
G.W. John *Castres, France*
E.J. Johns *Birmingham*
R.S.G. Jones *Oxford*
P.A.T. Kelly *Edinburgh*
D.A. Kendall *Nottingham*
C. Kennedy *Glasgow*
I. Kitchen *Guildford*
N.R. Kitteringham *Liverpool*
R.Z. Kozlowski *Oxford*
S. Lazareno *London*
R.A.J. Lefebvre *Ghent, Belgium*
J. Llenas *Barcelona, Spain*
A.T. McKnight *Cambridge*
C.A. Maggi *Florence, Italy*
I.G. Marshall *Glasgow*
Janice M. Marshall *Birmingham*

G. Martin *Beckenham*
A. Mathie *London*
P.K. Moore *London*
H. Nilsson *Aarhus, Denmark*
H. Osswald *Tübingen, Germany*
F.L. Pearce *London*
J.D. Pearson *London*
U. Quast *Tübingen, Germany*
A.G. Ramage *London*
P.J. Roberts *Bristol*
W.C. Sessa *New Haven, USA*
N. Shankley *London*
N.L. Simmons *Newcastle*
P.G. Skett *Glasgow*
P. Sneddon *Glasgow*
S. Clare Stanford *London*
K. Starke *Freiburg, Germany*
R.J. Summers *Melbourne, Australia*
J. Tamargo *Madrid, Spain*
C. Thiernemann *London*
M.D. Tricklebank *Basle, Switzerland*
T.J. Verbeuren *Suresnes, France*
R.R. Vollmer *Pittsburgh, USA*
Cherry L. Wainwright *Glasgow*
T.D. Warner *London*
K.J. Watling *Boston, USA*
J. Westwick *Bath*
K.I. Williams *Bath*
V.G. Wilson *Nottingham*
E.H.F. Wong *Milan, Italy*
S. Wonnacott *Bath*
B. Woodward *Bath*

Corresponding Editors

P.R. Adams *Stony Brook, U.S.A.*
C. Bell *Dublin*
F.E. Bloom *La Jolla, U.S.A.*
A.L.A. Boura *Newcastle, Australia*
N.J. Dun *Toledo, U.S.A.*
R.F. Furchgott *New York, U.S.A.*
T. Godfraind *Brussels, Belgium*
S.Z. Langer *Paris, France*

R.J. Miller *Chicago, U.S.A.*
R.C. Murphy *Denver, U.S.A.*
E. Muscholl *Mainz, Germany*
R.A. North *Geneva, Switzerland*
M. Otsuka *Tokyo, Japan*
M.J. Rand *Melbourne, Australia*
S. Rosell *Södertälje, Sweden*
P. Seeman *Toronto, Canada*

L. Szekeres *Szeged, Hungary*
B. Uvnas *Stockholm, Sweden*
P.A. Van Zwieten *Amsterdam, Netherlands*
V.M. Varagić *Belgrade, Yugoslavia*
G. Velo *Verona, Italy*
Wang Zhen Gang *Beijing, China*
M.B.H. Youdim *Haifa, Israel*

Submission of manuscripts: Manuscripts (two copies) should be sent to The Editorial Office, British Journal of Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE.

Authors should consult the Instructions to Authors and the Nomenclature Guidelines for Authors in Vol. 117, 389–399. These Instructions and Guidelines also appear with the journal Index for Volumes 114–116, 1995. A checklist of the essential requirements is summarised in each issue of the journal, or as the last page of the issue.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the *British Pharmacological Society* wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the *British Pharmacological Society*, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

The *British Journal of Pharmacology* is published by Stockton Press, a division of Macmillan Press Ltd. It is the official publication of the British Pharmacological Society.

Scope The *British Journal of Pharmacology* is published twice a month. It welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, Excerpta Medica, BIOSIS, CABS, CINAHL and Index Medicus.

Editorial Manuscripts (plus two copies) and all editorial correspondence should be sent to: The Editorial Office, *British Journal of Pharmacology*, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. Tel: +44 (0)181 767 6765; Fax: +44 (0)181 767 5645.

Advertisements Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex CM6 1AP, UK. Tel: +44 (0)1371 874613; Fax: +44 (0)1371 872273.

Publisher All business correspondence, supplement enquiries and reprint requests should be addressed to *British Journal of Pharmacology*, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526. Publisher: Marija Vukovojac. Production Controller: Nicci Crawley. Supplement Production Controller: Simone Larché

Subscriptions – EU/Rest of World Subscription price per annum (3 volumes, 24 issues) £655, rest of world £735 (Surface mail) £880 (Airmail), or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to *Macmillan Magazines* and sent to: The Subscription Department, Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EC territories should add sales tax at the local rate.

Subscriptions – USA USA subscribers call toll free 1-800-221-2123 or send check/money order/credit card details to: Stockton Press, 345 Park Avenue South, 10th Floor, New York, NY 10010-1707; Tel: +1 212 689 9200, Fax: +1 212 689 9711. USA annual subscription rates (institutional/corporate): \$1170 (surface) \$1400 (airmail). Individual making personal payment: \$240.

British Journal of Pharmacology (ISSN 0007-1188) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$1170 per annum (surface). 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel NJ 07001.

Reprints of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526.

Copyright © 1996 Stockton Press
ISSN 0007-1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007-1188/96 \$12.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

1997 KEYSTONE SYMPOSIA CONFERENCES

CONFERENCE (MAX. ATTENDANCE)	SITE • DATE	ORGANIZERS
Abstract Deadline: September 4, 1996 • Early Registration Deadline: October 2, 1996		
A1 Growth Control (800)	Keystone • 1/4-10	Charles J. Sherr and Tony Hunter
A2 Bone, Cartilage & Collagen: Growth & Differentiation (350)	Santa Fe • 1/7-12	John T. Potts, Jr., Stephen Krane and Henry Kronenberg
A3 Ocular Cell and Molecular Biology (400)	Tamarron • 1/7-12	Steven E. Wilson and Joe G. Hollyfield
J1 Molecular and Cellular Biology of Apicomplexan Protozoa (200)	Park City • 1/7-12	Carolyn Petersen and Michael W. White
J2 Innate Immunity: Non-Clonal Host Defense Mechanisms (200)	Park City • 1/7-12	Gill Diamond, Anne H. Fortier and Albert Bendelac
A4 B Lymphocytes in Health and Disease (400)	Steamboat Springs • 1/10-16	Maureen C. Howard, Norman R. Klinman and Max D. Cooper
J3 The Adipose Cell: Molecular Aspects of Differentiation, Gene Expression and Metabolic Regulation in the Normal Cell and Obese Models (200)	Park City • 1/15-21	Vincent C. Manganiello and Constantine Londos
J4 Insulin Action & Secretion in NIDDM (200)	Park City • 1/15-21	Ira D. Goldfine and Sam Cushman
Abstract Deadline: September 18, 1996 • Early Registration Deadline: October 16, 1996		
B1 Evolution of Plant Development (600)	Taos • 1/20-26	Susan R. Wessler, Michael Freeling and Elliot M. Meyerowitz
J5 Inflammation, Growth-Regulatory Molecules and Atherosclerosis (500)	Keystone • 1/20-26	Russell Ross and Michael A. Gimbrone, Jr.
J6 Immunologic Aspects of Cardiovascular Disease (300)	Keystone • 1/20-26	Noel R. Rose, Ahvie Herskowitz and Fred P. Sanfilippo
B2 Lipid Mediators: Recent Advances in Molecular Biology, Understanding of Regulation and Pharmacology (300)	Keystone • 1/26-31	Robert C. Murphy and Stephen M. Prescott
B3 Tolerance and Autoimmunity (800)	Keystone • 1/27-2/2	Tak W. Mak, Hans Wigzell and Irving Weissman
Abstract Deadline: October 1, 1996 • Early Registration Deadline: November 1, 1996		
C1 Molecular Mechanisms in Alzheimer's Disease (400)	Tamarron • 2/1-6	Bruce A. Yankner and Allen D. Roses
J7 RNA-Protein Interactions (300)	Taos • 2/1-6	Bert L. Semler and Peter Sarnow
J8 Aminoacyl tRNA Synthetases in Biology & Disease (200)	Taos • 2/1-6	Susan A. Martinis, Karin Musier-Forsyth and Charles W. Carter, Jr.
C2 Cellular Immunology and the Immunotherapy of Cancer - III (400)	Copper Mtn • 2/1-7	Michael T. Lotze and Olivera J. Finn
C3 Frontiers of NMR in Molecular Biology - V (600)	Taos • 2/6-11	Gerhard Wagner, Stephen W. Fesik and Stanley J. Opella
C4 Hematopoiesis (400)	Tamarron • 2/10-16	David W. Golde and Judith C. Gasson
C5 Molecular Mechanisms of Evolution: Structure, Function, Expression and Regulation of Genes and Proteins (350)	Santa Fe • 2/16-21	Dennis A. Powers, Franklin G. Berger, Caro-Beth Stewart and Douglas L. Crawford
C6 Apoptosis and Programmed Cell Death (400)	Tamarron • 2/18-23	J. John Cohen and John A. Cidlowski
Abstract Deadline: October 15, 1996 • Early Registration Deadline: November 15, 1996		
D1 Biology of Sarcomas - II: Molecular, Pathologic and Oncologic Aspects of Mesenchymal Growth and Differentiation (400)	Copper Mtn • 2/22-27	Richard B. Womer, Lee J. Helman and Frederic G. Barr
D2 Functional Organization of the Nucleus (350)	Santa Fe • 2/23-28	Larry R. Gerace, Christine Guthrie and Alan P. Wolffe
D3 Transposition and Site-Specific Recombination (350)	Santa Fe • 3/1-7	Jef D. Boeke, Nigel D.F. Grindley and Suzanne B. Sandmeyer
X1 Protein Folding, Modification and Transport in the Early Secretory Pathway (300)	Taos • 3/3-9	Randal J. Kaufman and Ari Helenius
X2 Processing of Peptide Hormones, Neurotransmitters, Growth Factors and Viral Proteins (300)	Taos • 3/3-9	Lloyd D. Fricker, Dennis Shields and Gary Thomas
D4 Germ Cell Differentiation (250)	Frisco • 3/12-17	Peter J. Donovan, Robert E. Braun and Tim B. Schedl
D5 Discovery and Development of Novel Therapeutic Agents for the 21st Century (400)	Tamarron • 3/16-21	Simon Campbell, James A. Bristol and Eric M. Gordon
D6 Mucosal Immunity: Cellular and Molecular Cross-Talk at Mucosal Surfaces (350)	Santa Fe • 3/23-28	Marian R. Neutra and Martin F. Kagnoff
Abstract Deadline: October 29, 1996 • Early Registration Deadline: December 2, 1996		
E1 The Role of Chemokines in Leukocyte Trafficking and Disease (400)	Copper Mtn • 3/31-4/5	Stephen W. Hunt, III, Steven L. Kunkel, John Westwick and Gregory J. LaRosa
X3 Temporal & Spatial Determinants of Specificity in Signal Transduction (400)	Keystone • 3/31-4/6	Alan R. Saltiel and Frank McCormick
X4 Signal Transduction by Cell Adhesion Receptors (400)	Keystone • 3/31-4/6	Rudolph L. Juliano and Ric Assoian
E2 Molecular Biology of Muscle Development (450)	Snowmass • 4/1-6	Leslie A. Leinwand, Charles P. Ordahl and Robert J. Schwartz
E3 Metabolic Engineering in Transgenic Plants (400)	Copper Mtn • 4/6-11	Richard A. Dixon and Charles J. Arntzen
E4 AIDS Pathogenesis (500)	Keystone • 4/8-13	Ronald C. Desrosiers, George M. Shaw and Michael Emerman
E5 Genetics of Human Cancer: Pathogenesis & Diagnosis (500)	Keystone • 4/13-19	Riccardo Dalla-Favera and Eric R. Fearon
E6 Molecular and Cellular Biology of Gene Therapy (500)	Snowbird • 4/13-19	Helen M. Blau and James M. Wilson
Designates joint sessions. Registration for one conference allows attendance at meetings in either.		

If you have ever applied for or attended a Keystone Symposia conference, you will be sent registration information.

Otherwise, write, call, or e-mail us to receive more information.

Keystone Symposia • Drawer 1630 • Silverthorne, CO 80498

Phone: (800) 253-0685 or (970) 262-1230 • Fax: (970) 262-1525 • E-mail: keystone@symposia.com

Visit our web site at <http://www.colorado.net/symposia> *All meetings are subject to change.

Subscription Order Form

To: Stockton Press, Direct Marketing, Houndmills,
Basingstoke, Hampshire, RG21 6XS, England
Tel: +44 (0)1256 51898 Fax: +44 (0)1256 28339

*IMPORTANT NOTICE FOR EUROPEAN UNION CUSTOMERS

Customers resident in the European Union are liable to
VAT/BTW/MOMS/TVA/MWST/FPA/IVA/TAV or equivalent when ordering.
You must either:
a) write your VAT (or equivalent) number in the space provided or
b) add tax at your country's rate to the total value of your order.
Customers receiving goods outside the European Union do not have to pay VAT.
Our UK VAT number is GB 199440621

☐ Yes, please record my subscription to **British Journal of Pharmacology** for one year (24 issues)

☐ I enclose a cheque for _____ made payable to Macmillan Magazines

VAT number (see notice above) _____

☐ Please charge _____ to my

Visa/Mastercard/Amex/Diners

Credit Card Account No.

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Account Name _____

Account address ☐ as opposite below OR ☐ please
specify _____

Signature _____

Expiry Date _____

1996 Subscription Rates

ISSN 0007 1188	One Year (24 Issues)
European Union*	£665
Rest of the World	£735

We welcome payment in your own currency, converted at the current rate.

Name (BLOCK CAPITALS) _____

Position _____

Address _____

Postal/Zip Code _____

Country _____

Tel: _____

Fax: _____



Subscription Order Form

To: Stockton Press, Journals Marketing
345 Park Avenue South, 10th Floor,
NY 10010-1707, USA
Tel: (212) 689 9200 Fax: (212) 689 9711
Toll Free: 800 221 2123

1996 Subscription Rates

ISSN 0007 1188	One Year (24 Issues)
European Union*	£665
Rest of the World	\$1170
Personal Rate	\$240 (payment by personal check or credit card only)

We welcome payment in your own currency, converted at the current rate.

☐ Yes, please record my subscription to **British Journal of Pharmacology** for one year (24 issues)

☐ I enclose a check for _____ made payable to Stockton Press

☐ Please charge _____ to my

Visa/Mastercard/Amex/Diners

Credit Card Account No.

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Account Name _____

Account address ☐ as opposite below OR ☐ please
specify _____

Signature _____

Expiry Date _____

Name (BLOCK CAPITALS) _____

Position _____

Address _____

Postal/Zip Code _____

Country _____

Tel: _____

Fax: _____



**NORTH
AMERICA**

LIBRARY RECOMMENDATION FORM

To: Librarian/Library Acquisition Committee

I have just reviewed a sample copy of the journal detailed overleaf entitled:

Please include it in your next serials review meeting with my recommendation.

(Further sample copies are available from Stockton Press, Direct Marketing, Houndmills, Basingstoke Hampshire RG21 6XS, UK)

I recommend the journal for the following reasons:

Name: _____ Position: _____

Department: _____

LIBRARY RECOMMENDATION FORM

To: Librarian/Library Acquisition Committee

I have just reviewed a sample copy of the journal detailed overleaf entitled:

Please include it in your next serials review meeting with my recommendation.

(Further sample copies are available from Stockton Press, Journals Marketing, 345 Park Avenue South, 10th Floor, NY 10010-1707. USA)

I recommend the journal for the following reasons:

Name: _____ Position: _____

Department: _____

SPECIAL REPORTS

- J. Mateo, P. Rotllán & M.T. Miras-Portugal Suramin - a powerful inhibitor of neural ecto-diadenosine polyphosphate hydrolase 1

- W. Zierhut & H.A. Ball Prevention of vascular nitroglycerin tolerance by inhibition of protein kinase C 3

PAPERS

- I.J. Chen, J.L. Yeh, Y.C. Lo, S.H. Sheu & Y.T. Lin Capsinolol: the first β -adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart 7

- P.E. Jensen Calphostin C-sensitive enhancements of force by lysophosphatidylinositol and diacylglycerols in mesenteric arteries from the rat 15

- F. Squadrito, D. Altavilla, G. Squadrito, G.M. Campo, M. Ioculano, P. Canale, F. Rossi, A. Saitta & A.P. Caputi Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock 23

- S. Guarini, C. Bazzani, G.M. Ricigliano, A. Bini, A. Tomasi & A. Bertolini Influence of ACTH-(1-24) on free radical levels in the blood of haemorrhage-shocked rats: direct *ex vivo* detection by electron spin resonance spectrometry 29

- J.-P. Valentin, R. Bonnafous & G.W. John Influence of the endothelium and nitric oxide on the contractile responses evoked by 5-HT_{1D} receptor agonists in the rabbit isolated saphenous vein 35

- G. Sitzler, O. Lenz, H. Kilter, K. La Rosee & M. Böhm Investigation of the negative inotropic effects of 17 β -oestradiol in human isolated myocardial tissues 43

- C.E. Wright & J.A. Agnus Effects of N-, P- and Q-type neuronal calcium channel antagonists on mammalian peripheral neurotransmission 49

- R. Masereeuw, M.M. Moons, P. Smits & F.G.M. Russel Glomerular filtration and saturable absorption of iohexol in the rat isolated perfused kidney 57

- F.P. Monnet, B.R. de Costa & W.D. Bowen Differentiation of σ ligand-activated receptor subtypes that modulate NMDA-evoked [³H]-noradrenaline release in rat hippocampal slices 65

- T. Kobayashi, K. Ikeda, T. Ichikawa, S. Togashi & T. Kumanishi Effects of sigma ligands on the cloned μ , δ - and κ -opioid receptors co-expressed with G-protein-activated K⁺ (GIRK) channel in *Xenopus* oocytes 73

- F.M. Kuenzi & N. Dale Effect of capsaicin and analogues on potassium and calcium currents and vanilloid receptors in *Xenopus* embryo spinal neurones 81

- A. Freitag, I. Wessler & K. Racké Adrenoceptor- and cholinceptor-mediated mechanisms in the regulation of 5-hydroxytryptamine release from isolated tracheae of newborn rabbits 91

- J. Cortijo, V. Villagrana, C. Navarrete, C. Sanz, L. Berto, A. Michel, P.A. Bonnet & E.J. Morcillo Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levromakalim 99

- E.A. Stein, S.A. Fuller, W.S. Edgemond & W.B. Campbell Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat 107

- P. Kotsonis & H. Majewski The structural requirements for phorbol esters to enhance noradrenaline and dopamine release from rat brain cortex 115

- W. Marszalec, J.-H. Song & T. Narahashi The effects of the muscle relaxant, CS-722, on synaptic activity of cultured neurones 126

- K. Mori, T. Saito, Y. Masuda & H. Nakaya Effects of class III antiarrhythmic drugs on the Na⁺-activated K⁺ channels in guinea-pig ventricular cells 133

- C. Dessy & T. Godfraind The effect of L-type calcium channel modulators on the mobilization of intracellular calcium stores in guinea-pig intestinal smooth muscle 142

- X. Norel, L. Walch, M. Costantino, C. Labat, I. Gorenne, E. Dulmet, F. Rossi & C. Brink M₁ and M₃ muscarinic receptors in human pulmonary arteries 149

- M.A. Noguera, M.D. Ivorra & P. D'Ocon Functional evidence of inverse agonism in vascular smooth muscle 158

- S.E. Smith, C.M. Man, P.K. Yip, E. Tang, A.G. Chapman & B.S. Meldrum Anticonvulsant effects of 7-nitroindazole in rodents with reflex epilepsy may result from L-arginine accumulation or a reduction in nitric oxide or L-citrulline formation 165

- F. Ruiz, M.C. Fournié-Zaluski, B.P. Roques & R. Maldonado Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism 174

CORRIGENDUM

183